Senseonics Reports Third-Quarter Results as Revenue Figures and Outlook Remain Unverified
Key Facts
Senseonics reported third-quarter results on November 9, 2026, but the revenue figures or updated annual outlook cited in the news headline could not be verified against a reliable, publicly accessible source. It is therefore not possible to attribute a specific third-quarter revenue figure or say the company raised its guidance after the results were released. In the background, the company reported second-quarter revenue of $14.5 million, up approximately 120% year over year. It also raised its 2026 revenue guidance range at the time to $62–66 million, from $60–64 million. Those figures applied to the second quarter and the guidance that followed it, not the third-quarter results reported on November 9.
In the first half of 2026, Senseonics recorded revenue of $26.2 million, compared with $12.9 million in the same period of 2025, an increase of $13.3 million, according to its filing with the U.S. Securities and Exchange Commission. The company said revenue growth was primarily linked to higher sales in the United States. It added that growth in its commission-based program and demand for Eversense 365 contributed to the increase, along with the end of Ascensia's share of revenue after its U.S. commercial rights were terminated. First-half data therefore provide context on the sales trajectory ahead of the third-quarter results, without specifying revenue for that quarter. First-quarter revenue alone was $11.7 million, up 87% year over year, according to company results published in May.
Following its second-quarter results, Senseonics raised its 2026 gross margin guidance to a range of 58%–61%, from 55%–58%. It also said U.S. revenue in the second quarter grew more than 150% year over year, and that the number of active prescribers rose about 130% over the same period. The company described shipment volume in that quarter as the highest in its history and linked the results to a period following the transfer of U.S. commercial operations for Eversense in-house. These remain reported second-quarter indicators and do not establish the third-quarter gross margin or any new change to the annual outlook. The previous revenue guidance had been raised after the second quarter to $62–66 million, from the prior range of $60–64 million.
Senseonics said its annual outlook takes into account the continued launch of Eversense 365 outside the United States, planned investment in direct-to-consumer marketing, sales and marketing initiatives, and the use of patient-assistance programs. In May, Chief Executive Tim Goodnow said first-quarter revenue and gross margin exceeded the company's expectations. He added that the company had secured more than $100 million in equity and debt financing to support the global launch of Eversense 365 and continue developing its programs. These commercial and financing statements provide background on the company's plans, but do not provide confirmed figures for third-quarter results. On October 26, the company announced the start of the first human study of its investigational Freedom system, designed to communicate directly with a mobile device without an external transmitter worn on the body.
SENS shares closed at $8.59 on November 6, ahead of the results announcement, according to EL7 data. That price reflects a session before the announcement and does not represent the market's reaction to the November 9 results. On development, Senseonics said it expects to begin a pivotal study of the Freedom system in 2027, with a potential commercial launch targeted for 2028. The company also listed two investor conferences in New York after the results announcement: the Stifel Healthcare Conference on November 10 and the Canaccord Genuity MedTech Forum on November 11. The two events are the next announced stops on the company's schedule, while any update to the annual figures remains unconfirmed in the available information.